Skip to main navigation
Skip to search
Skip to main content
Amsterdam UMC Home
Help & FAQ
Link opens in a new tab
Search content at Amsterdam UMC
Home
Researchers
Departments & Research Institutes
Projects & Funding
Publications
Datasets
Prizes
Activities
Courses
Cohorts
Press/Media
Impact
Switching between biological agents
R. F. van Vollenhoven
pre-AMC
Research output
:
Contribution to journal
›
Article
›
Academic
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Switching between biological agents'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Tumor Necrosis Factor-α
100%
Biological Agents
100%
Stockholm
33%
Treatment Effect
33%
Etanercept
33%
Infliximab
33%
Adalimumab
33%
Clinical Scenarios
33%
Sequential Therapy
33%
Time Waste
33%
TNF-α Antagonists
33%
Immunology and Microbiology
Tumor Necrosis Factor
100%
Biological Product
100%
Tumor Necrosis Factor Alpha
100%
Infliximab
50%
Etanercept
50%
Adalimumab
50%
Medicine and Dentistry
Tumor Necrosis Factor
100%
Biological Product
100%
Treatment Effect
25%
Etanercept
25%
Infliximab
25%
Adalimumab
25%
Nursing and Health Professions
Biological Product
100%
Tumor Necrosis Factor
100%
Etanercept
25%
Infliximab
25%
Adalimumab
25%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Biological Product
100%
Etanercept
25%
Adalimumab
25%
Infliximab
25%
Neuroscience
Tumor Necrosis Factor Alpha
100%
Etanercept
50%
Infliximab
50%
Adalimumab
50%